November 15, 2022 7:57am
Earnings: Biostage (OTCQB: BSTG) had a Q3 net loss of -$1.1 million or -$0.10 per share with a cash position of $2.97 million and a Q1/2023 runway.
Indications: 1 Negative Indication, 7 Positive Indication and 1 Pump/Promote
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
I don’t seek fame, do podcasts or give speeches, what I do is keep writing this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write - truth!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.61% or (+206 points), S&P futures are UP +1.01% or (+40 points) and NASDAQ futures are UP +1.56% or (+182 points) early in the pre-open – so far,
Stock futures rose Tuesday as traders looked ahead to the release of more key U.S. inflation data,
European markets subdued as investors measure economic outlook,
Asia-Pacific markets were mostly higher.
We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …
The Dow, S&P and the Nasdaq fell; trading was choppy throughout the day, with the market struggling for direction throughout the session. The Dow closed DOWN -211.16 points (-0.63%), the S&P closed DOWN -35.60 points (-0.89%) while the Nasdaq closed DOWN -127.11 points (-1.12%
Economic Data Docket: the producer price index, a measure of wholesale inflation to be released.
The PPI is expected to rise 0.5% in October vs. the previous month. And wholesale inflation is expected to jump 8.3% from a year ago.
Investors will also hear from and study comments from Philadelphia Fed President Patrick Harker, Fed Governor Lisa Cook and Fed Vice Chair for Supervision Michael Barr.
Monday’s (11/14) … RegMed Investors’ (RMi) closing bell: “the speed bumps slow the action” … https://www.regmedinvestors.com/articles/12699
Ebb and flow:
Q4 – November - 7 negative and 4 positive closes
· October -1 neutral, 11 positive and 9 negative closes
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
AxoGen (AXGN) closed down -$0.76 to $12.21 with a positive +$0.35 or +2.87% pre-open indication.
BioLife Solutions (BLFS) closed down -$1.85 to $23.22 after Friday’s +$0.37 and Thursday’s +$7.40 with a positive +$1.15 or +4.95% pre-open indication
Caribou Biosciences (CRBU) closed down -$0.11 to $10.27 with a positive +$0.51 or +4.97% pre-open indication
CRISPR Therapeutics (CRSP) closed down -$0.57 to $59.78 after Friday’s +$5.66 and Thursday’s +$5.76 with a positive +$1.72 or +2.88% pre-open indication
Intellia therapeutics (NTLA) closed down -$1.65 to $53.30 with a positive +$0.73 or +1.37% pre-open indication.
Ultragenyx Pharmaceuticals (RARE) closed down -$1.30 to $35.25 after Friday’s -1.03 and Thursday’s +$3.86 with a positive +$0.59 or +1.66% pre-open indication
Vericel (VCEL) closed down -$0.71 to $23.09 after Friday’s +$1.39 and Thursday’s +$4.76 with a positive +$0.16 or +0.68% pre-open indication
Chinook Therapeutics (KDNY) closed down -$0.57 to $59.78 after Friday’s +$0.24 with a negative -$0.22 or -1.01% pre-open indication
Puff/Pump and Promote: Maintaining SELL as earnings LPS (loss-per-share) says NOTHING on future without financing. Question: What or which U.S. investor group would EVEN consider "participating" in an offering?
Biostage (OTCQB: BSTG) closed up +$0.71 with 239 shares traded after being flat on Friday with 8 shares traded to $6.19 after Thursday’s -$0.58 with 160 shares traded, Wednesday’s -$0.01 with 314 shares traded, Thursday’s +$0.76 with 1,880 shares traded and last Friday’s +$0.01 with 2,953 shares traded <3-month average = 2,443 shares>
A DRAFT prospectus is filed … SEC Form S-1/A …https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=117017206&type=HTML&formType=S-1%2FA&dateFiled=2022-10-27&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage . Questions arise as to draft prospectus statement of non-reliance of past financials? Hey, CFO Joe some of us have copies of lost “payables”?
The BOTTOM LINE: If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Reiterating, “I try to keep it simple … and short …
Defining the terms of my written words, “An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation. The sole provision is that it provides insight to provide some vision into a likely course of action.”
I also tend to be …EARLY in recommendations; I learned very early (military), if you weren’t 5 minutes early for a meeting, you were 10 minutes late – be early in portfolio deliberations …
Always’ remember and do NOT forget, today’s investors’ gold is a trader’s disposable tin.
We are still in earnings season; focus is on “runways” or cash positions: who’s got it, who doesn’t, and when will cash run-out. With capital markets closed or tight, companies better be conserving.
Reiterating, “Kenny Storch at BTIG, states there are 226 public biotech companies trading below cash currently; with 1 out of 5 in the Nasdaq Biotech Index trading below cash.”
What’s SAFE … “No one company is immune in the sector and this market of rolling downdrafts?”
Guidance on investing,
- “When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.”
- CEO salaries, spending within G&A are totally OUT-OF-WHACK; these are companies in early development stages and will be for years without products in most cases not like the tech companies, whose CEOs and management teams think sector management teams should be compared to for bi-weekly cash and “beanies”!
My guide to 'good news seems to be bad news' and 'bad news is good news. 'In normal times, no one really questions whether good news in the economy is actually good.
Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that investors are safer on the sidelines as again … earnings are coming.
Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.